Ponzoni, I.; Sebastian-Perez, V.; Martinez, M. J.; Roca, C.; De la Cruz, C.; Perez, C.; Cravero, F.; Vazquez, G.; Paez, J. A.; Diaz, M. F.; Campillo, N. E.
[2019]. QSAR classification models for predicting the activity of inhibitors of Beta-Secretase (BACE1) associated with Alzheimer's disease. Sci. Rep. 2019, 9, 9102.
Posa, D.; Martinez-Gonzalez, L.; Bartolome, F.; Nagaraj, S.; Porras, G.; Martinez, A.; Martin-Requero, A.
[2018]. Recapitulation of pathological TDP-43 features in immortalized lymphocytes from sporadic ALS patients. Mol. Neurobiol. 2018, doi: 10.1007/s12035-018-1249-8.
Kraft, C.; Boya, P.; Codogno, P.; Elazar, Z.; Eskelinen, E. L.; Farres, J.; Kirkin, V.; Jungbluth, H.; Martinez, A.; Pless, O.; Primard, C.; Proikas-Cezanne, T.; Simonsen, A.; Reggiori, F.
[2018]. Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy. Autophagy 2018, 1-5.
Decara, J.; Serrano, A.; Pavon, F. J.; Rivera, P.; Arco, R.; Gavito, A.; Vargas, A.; Navarro, J. A.; Tovar, R.; Lopez-Gambero, A. J.; Martinez, A.; Suarez, J.; Rodriguez de Fonseca, F.; Baixeras, E.
[2018]. The adiponectin promoter activator NP-1 induces high levels of circulating TNFalpha and weight loss in obese (fa/fa) Zucker rats. Sci. Rep. 2018, 8, 9858.
Cheng, Y.; Desse, S.; Martinez, A.; Worthen, R. J.; Jope, R. S.; Beurel, E.
[2018]. TNFalpha disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain Behav. Immun. 2018, 69, 556-567.
Benek, O.; Hroch, L.; Aitken, L.; Gunn-Moore, F.; Vinklarova, L.; Kuca, K.; Perez, D. I.; Perez, C.; Martinez, A.; Fisar, Z.; Musilek, K.
[2018]. 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. J. Enzyme Inhib. Med. Chem. 2018, 33, 665-670.
Alten, B.; Yesiltepe, M.; Bayraktar, E.; Tas, S. T.; Gocmen, A. Y.; Kursungoz, C.; Martinez, A.; Sara, Y.
[2018]. High-fructose corn syrup consumption in adolescent rats causes bipolar-like behavioural phenotype with hyperexcitability in hippocampal CA3-CA1 synapses. Br. J. Pharmacol. 2018, 175, 4450-4463.
Sebastián-Pérez, V.; Hendrickx, S.; Munday, J. C.; Kalejaiye, T.; Martínez, A.; Campillo, N. E.; de Koning, H.; Caljon, G.; Maes, L.; Gil, C.
[2018]. Cyclic nucleotide specific phosphodiesterases as potential drug targets for anti-Leishmania therapy. Antimicrob. Agents Chemother. 2018, 62, e00603-18.
Chierrito, T. P. C.; Pedersoli-Mantoani, S.; Roca, C.; Sebastian-Perez, V.; Martinez-Gonzalez, L.; Perez, D. I.; Perez, C.; Canales, A.; Cañada, F. J.; Campillo, N. E.; Carvalho, I.; Martinez, A.
[2018]. Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur. J. Med. Chem. 2018, 145, 431-444.
Paez, J. A.; Campillo, N. E.
[2018]. Innovative therapeutic potential of cannabinoid receptors as targets in Alzheimer's disease and less well-known diseases. Curr. Med. Chem., 2018, 25, 1-38.
Del Cerro, P.; Alquezar, C.; Bartolome, F.; Gonzalez-Naranjo, P.; Perez, C.; Carro, E.; Paez, J. A.; Campillo, N. E.; Martin-Requero, A.
[2018]. Activation of the cannabinoid type 2 receptor by a novel indazole derivative normalizes the survival pattern of lymphoblasts from patients with late-onset Alzheimer's disease. CNS Drugs 2018, 32, 579-591.
Roca, C.; Requena, C.; Sebastian-Perez, V.; Malhotra, S.; Radoux, C.; Perez, C.; Martinez, A.; Antonio Paez, J.; Blundell, T. L.; Campillo, N. E.
[2018]. . Identification of new allosteric sites and modulators of AChE through computational and experimental tools. J. Enzyme Inhib. Med. Chem. 2018, 33, 1034-1047.
Gandini, A.; Bartolini, M.; Tedesco, D.; Martinez-Gonzalez, L.; Roca, C.; Campillo, N. E.; Zaldivar-Diez, J.; Perez, C.; Zuccheri, G.; Miti, A.; Petralla, A.; Monti, B.; Rossi, M.; Moda, F.; Legname, G.; Martinez, A.; Bolognesi, M. L.
[2018]. Tau-centric multitarget approach for Alzheimer's disease: Development of first-in-class dual Glycogen Synthase Kinase 3beta and tau-aggregation inhibitors. J. Med. Chem. 2018, 61, 7640-7656.
Roca, C.; Martinez-Gonzalez, L.; Daniel-Mozo, M.; Sastre, J.; Infantes, L.; Mansilla, A.; Chaves-Sanjuan, A.; Gonzalez Rubio, J. M.; Gil, C.; Cañada, F. J.; Martinez, A.; Sanchez-Barrena, M. J.; Campillo, N. E.
[2018]. Deciphering the inhibition of the neuronal calcium sensor 1 and the guanine exchange factor Ric8a with a small phenothiazine molecule for the rational generation of therapeutic synapse function regulators. J. Med. Chem. 2018, 61, 5910-5921.
Sánchez-Cruz, A.; Villarejo-Zori, B.; Marchena, M.; Zaldivar-Díez, J.; Palomo, V.; Gil, C.; Lizasoaín, I.; de la Villa, P.; Martínez, A.; de la Rosa, E. J.; Hernández-Sánchez, C.
[2018]. Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa. Mol. Neurodegener. 2018, 13, 19.
Bartolome, F.; de la Cueva, M.; Pascual, C.; Antequera, D.; Fernandez, T.; Gil, C.; Martinez, A.; Carro, E.
[2018]. Amyloid beta-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition. Alzheimer’s Res. Ther. 2018, 10, 24.
Ed. L. Rivas and C. Gil.
[2018]. Drug Discovery for Leishmaniasis. Ed. L. Rivas and C. Gil. Royal Society of Chemistry. 2018, ISBN 978-1-78262-889-7.
Martinez, A.; Gil, C.
[2018]. “Medicinal chemistry strategies to discover new leishmanicidal drugs” en Drug Discovery for Leishmaniasis. Ed. L. Rivas and C. Gil. Royal Society of Chemistry. 2018, 153-178.
Roca, C.; Sebastián-Pérez, V.; Campillo, N. E.
[2018]. "In silico Tools for Target Identification and Drug Molecular Docking in Leishmania" en Drug Discovery for Leishmaniasis. Ed. L. Rivas and C. Gil. Royal Society of Chemistry. 2018, 130-152
Ed. A. Martinez and C. Gil.
[2017]. Comprehensive Medicinal Chemistry III Ed. Vol 1: General Perspectives-The future of Drug Discovery. Ed. A. Martinez and C. Gil. Elsevier. 2017, ISBN 9780128032008
